↓ Skip to main content

Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk

Overview of attention for article published in Cardiovascular Diabetology, March 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Published in
Cardiovascular Diabetology, March 2017
DOI 10.1186/s12933-017-0515-9
Pubmed ID
Authors

Katherine Kearney, Darren Tomlinson, Kerrie Smith, Ramzi Ajjan

Abstract

An enhanced thrombotic environment and premature atherosclerosis are key factors for the increased cardiovascular risk in diabetes. The occlusive vascular thrombus, formed secondary to interactions between platelets and coagulation proteins, is composed of a skeleton of fibrin fibres with cellular elements embedded in this network. Diabetes is characterised by quantitative and qualitative changes in coagulation proteins, which collectively increase resistance to fibrinolysis, consequently augmenting thrombosis risk. Current long-term therapies to prevent arterial occlusion in diabetes are focussed on anti-platelet agents, a strategy that fails to address the contribution of coagulation proteins to the enhanced thrombotic milieu. Moreover, antiplatelet treatment is associated with bleeding complications, particularly with newer agents and more aggressive combination therapies, questioning the safety of this approach. Therefore, to safely control thrombosis risk in diabetes, an alternative approach is required with the fibrin network representing a credible therapeutic target. In the current review, we address diabetes-specific mechanistic pathways responsible for hypofibrinolysis including the role of clot structure, defects in the fibrinolytic system and increased incorporation of anti-fibrinolytic proteins into the clot. Future anti-thrombotic therapeutic options are discussed with special emphasis on the potential advantages of modulating incorporation of the anti-fibrinolytic proteins into fibrin networks. This latter approach carries theoretical advantages, including specificity for diabetes, ability to target a particular protein with a possible favourable risk of bleeding. The development of alternative treatment strategies to better control residual thrombosis risk in diabetes will help to reduce vascular events, which remain the main cause of mortality in this condition.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 20%
Student > Bachelor 11 18%
Researcher 7 11%
Student > Doctoral Student 6 10%
Student > Postgraduate 5 8%
Other 14 23%
Unknown 6 10%
Readers by discipline Count As %
Medicine and Dentistry 21 34%
Biochemistry, Genetics and Molecular Biology 9 15%
Agricultural and Biological Sciences 7 11%
Engineering 4 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Other 5 8%
Unknown 11 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2017.
All research outputs
#5,850,327
of 11,338,956 outputs
Outputs from Cardiovascular Diabetology
#213
of 661 outputs
Outputs of similar age
#103,014
of 257,024 outputs
Outputs of similar age from Cardiovascular Diabetology
#12
of 20 outputs
Altmetric has tracked 11,338,956 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 661 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 257,024 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.